Compare Crispr Therapeutics AG (CRSP) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PulteGroup, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.36 (market cap $4.97B), while PulteGroup, Inc. trades at $125.43 (market cap $23.73B). The key difference: PulteGroup, Inc. is far larger — about 4.8× Crispr Therapeutics AG's market cap, and PulteGroup, Inc. pays a 0.83% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PHM | |
|---|---|---|
Market Cap | $4.97B | $23.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $142.56 |
52-Week Low | $44.34 | $108.00 |
Enterprise Value | $3.32B | $23.69B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
PulteGroup (PHM) trades at $123.75, down 0.8% on the day, with a bullish technical signal but mixed recent earnings. The stock shows strong profitability with a 12.14% net margin and attractive valuation at a P/E of 11.97. Recent news highlights new community developments and market sensitivity to mortgage rates. Cash flow trends improved in 2025 with net cash flow of $355 million.
Outlook remains cautiously optimistic with a consensus price target of $146, implying 18% upside. Risks include housing affordability pressures and recent earnings misses. Analyst sentiment is balanced with 45% buy ratings. The stock's valuation and dividend support a constructive view amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
